Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2026 04:31 ET | Source: Research and Markets

Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Outlook

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Peptide Drug Conjugate Market Opportunity, Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Clinical Trials Outlook 2031" report has...
April 21, 2026 04:27 ET | Source: Research and Markets

Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - Size, Regulatory Approvals, Proprietary Technologies, Therapeutic Applications

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Targeted Alpha Therapy Market Size, Regulatory Approvals, Proprietary Technologies, Therapeutic Applications & Clinical Trials Insight 2030"...
April 21, 2026 04:13 ET | Source: Research and Markets

Trispecific Antibodies Market Landscape Report 2026: Opportunity and Proprietary Insights - 90 Trispecific Antibodies by Company, Country, Indication & Phase

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Trispecific Antibodies Market Opportunity, Proprietary Technologies & Clinical Trials Insight 2026" report has been added to ...
April 20, 2026 05:58 ET | Source: Research and Markets

Biologics Contract Research Organization Market Industry Trends and Forecasts 2026-2035: Big Pharma Outsources 45% of R&D as 160 Specialized CROs Reshape the Biopharmaceutical Research Landscape

Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "Biologics Contract Research Organization Market: Industry Trends and Global Forecasts - Distribution by Type of Biologic, Scale of Operation,...
April 01, 2026 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human,...
March 19, 2026 06:00 ET | Source: Priavoid GmbH

Priavoid Presents Preclinical Proof-of-Concept for PRI-101 Demonstrating α-synuclein Aggregate Disassembly at AD/PD™ 2026

PRI-101 inhibited aggregation of α-synuclein and actively disassembled fibrils across in vitro and in vivo models relevant to Parkinson’s disease Dusseldorf, Germany, March 19, 2026 - Priavoid GmbH...
March 12, 2026 10:30 ET | Source: Research and Markets

Pharmaceuticals and Biotechnology Preclinical Stage Partnering Terms and Agreements Report 2026 with Directory of 1,750 Deals Signed Since 2020 by Company, Phase, Therapeutic Area, and Technology

Dublin, March 12, 2026 (GLOBE NEWSWIRE) -- The "Preclinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026" report has been added to ResearchAndMarkets.com's...
March 11, 2026 04:30 ET | Source: Commit Biologics

Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic

Commit Biologics appoints seasoned biotech entrepreneur Thomas L. F. Montgomery Andresen, PhD, as Chief Executive Officer.
March 03, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Preclinical data shines: >85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler safety profile
February 27, 2026 04:02 ET | Source: Research and Markets

Global Ferroptosis Targeting Therapy Market Opportunity Report 2026: Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insights By Company, Country, Indication & Phase

Dublin, Feb. 27, 2026 (GLOBE NEWSWIRE) -- The "Global Ferroptosis Targeting Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insight 2026"...